Literature DB >> 2454366

Studies on the mode of vasodilating action of carvedilol.

G Sponer1, K Strein, B Müller-Beckmann, W Bartsch.   

Abstract

Investigations were performed on isolated rat aortic strips and in pithed rats in order to elucidate the mechanism of vasorelaxation or the acute blood pressure lowering effect induced by carvedilol. In particular, the possible role of the beta-receptor-stimulating activities or alpha-blocking properties has been investigated. beta 2-stimulation can be ruled out, since preincubation of isolated vessels with the beta 2-receptor blocker ICI 118.551 does not influence the vasorelaxing activity of carvedilol. Additionally, its optical enantiomers also induce the same vasorelaxing effect in vitro. In contrast to the standard alpha-blocking agents phentolamine or prazosin, carvedilol does not inhibit effects of alpha-receptor agonists at hypotensive doses, but inhibition of the effects of alpha-receptor agonists has been found in vitro and in vivo at high concentrations or doses and indicates a potential alpha-blocking activity of carvedilol. For example, the dose required for a specific inhibitory effect on norepinephrine responses observed in pithed rats is at least 20 times higher than that required for a decrease in blood pressure in spontaneously hypertensive rats. Furthermore, the alpha-blocking activity is at least 20 times lower than the beta-blocking activity, whereas hypotension and beta-blockade can be observed in intact animals after acute administration in the same dose range of carvedilol. It can therefore be assumed that the alpha-blocking activity does not contribute substantially to the decrease in blood pressure at doses normally used. It is suggested that a not yet defined postreceptor mechanism is involved in the vasorelaxing and acute blood pressure lowering activity of carvedilol.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2454366

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  13 in total

1.  Long-term hemodynamic effects of antihypertensive treatment.

Authors:  P Lund-Johansen; P Omvik; J E Nordrehaug
Journal:  Clin Investig       Date:  1992

2.  Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan.

Authors:  M Kohno; T Takeda; M Ishii; T Saruta; Y Mizuno; M Yoshimura; S Kubo; K Fukiyama; M Fujishima
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Analysis of the mechanism underlying the vasodilator action of carvedilol in pithed spontaneously hypertensive rats.

Authors:  H Hashimoto; M Tanaka; A Kanda; A Akashi
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Vasodilating mechanism and response to physiological pressor stimuli of acute doses of carvedilol compared with labetalol, propranolol and hydralazine.

Authors:  B Tomlinson; F Bompart; B R Graham; J B Liu; B N Prichard
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 5.  Progress in antihypertensive therapy with a multiple-action drug.

Authors:  B N Prichard; B Tomlinson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 6.  Combined action drugs in the treatment of hypertension.

Authors:  L Hansson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  The dose dependency of the alpha- and beta-adrenoceptor antagonist activity of carvedilol in man.

Authors:  T C Tham; S Guy; B J McDermott; R G Shanks; J G Riddell
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

Review 8.  Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D McTavish; D Campoli-Richards; E M Sorkin
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

Review 9.  Antihypertensive profile of carvedilol.

Authors:  W Meyer-Sabellek; B Agrawal
Journal:  Clin Investig       Date:  1992

10.  Acute hemodynamic effects of carvedilol in comparison with propranolol in patients with coronary heart disease.

Authors:  T Wendt
Journal:  Clin Investig       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.